Measurement of Oncometabolites D-2-Hydroxyglutaric Acid and L-2-Hydroxyglutaric Acid.

[1]  R. Collins,et al.  The importance of plasma D‐2HG measurement in screening for IDH mutations in acute myeloid leukaemia , 2016, British journal of haematology.

[2]  E. Callaway.  Dogs thwart effort to eradicate Guinea worm , 2016, Nature.

[3]  Shawn M. Gillespie,et al.  Insulator dysfunction and oncogene activation in IDH mutant gliomas , 2015, Nature.

[4]  J. Loscalzo,et al.  Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. , 2015, Cell metabolism.

[5]  Patrick B. Grinaway,et al.  Hypoxia Induces Production of L-2-Hydroxyglutarate. , 2015, Cell metabolism.

[6]  T. Nakada,et al.  Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy , 2014, Acta neuropathologica communications.

[7]  Sejong Bae,et al.  A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody , 2014 .

[8]  Claude Preudhomme,et al.  Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Jeffrey W. Clark,et al.  Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma , 2014, Clinical Cancer Research.

[10]  D. Rakheja,et al.  The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms , 2013, Front. Oncol..

[11]  E. Sistermans,et al.  Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. , 2013, American journal of human genetics.

[12]  H. Kohrt,et al.  2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels , 2013, Leukemia & lymphoma.

[13]  D. Margolis,et al.  Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. , 2012, Blood.

[14]  Derek Y. Chiang,et al.  Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets with Glioblastomas , 2012, Oncogene.

[15]  Erwin G. Van Meir,et al.  Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma , 2012, Journal of Molecular Medicine.

[16]  Ovidiu C. Andronesi,et al.  Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.

[17]  D. Muzny,et al.  High incidence of IDH mutations in acute myeloid leukaemia with cuplike nuclei , 2011, British journal of haematology.

[18]  Dinesh Rakheja,et al.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.

[19]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[20]  R. Klose,et al.  The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases , 2011, EMBO reports.

[21]  D. Rakheja,et al.  Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate , 2011, Tumor Biology.

[22]  R. Deberardinis,et al.  Isocitrate dehydrogenase 1/2 mutational analyses and 2‐hydroxyglutarate measurements in Wilms tumors , 2011, Pediatric blood & cancer.

[23]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[24]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[25]  A. von Deimling,et al.  Increased levels of 2‐hydroxyglutarate in AML patients with IDH1‐R132H and IDH2‐R140Q mutations , 2010, European journal of haematology.

[26]  E. Holme,et al.  IDH2 Mutations in Patients with d-2-Hydroxyglutaric Aciduria , 2010, Science.

[27]  W. van Putten,et al.  Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. , 2010, Blood.

[28]  Michael Heuser,et al.  Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. , 2010, Blood.

[29]  D. Zafeiriou,et al.  An overview of L‐2‐hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype–phenotype study , 2010, Human mutation.

[30]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[31]  B. Maranda,et al.  Evidence for genetic heterogeneity in D‐2‐hydroxyglutaric aciduria , 2010, Human mutation.

[32]  Tak W. Mak,et al.  Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations , 2010, The Journal of experimental medicine.

[33]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[34]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[35]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[36]  E. Schaftingen,et al.  l-2-Hydroxyglutaric aciduria, a disorder of metabolite repair , 2009, Journal of Inherited Metabolic Disease.

[37]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[38]  M. Topcu,et al.  L-2-hydroxyglutaric aciduria and brain tumors in children with mutations in the L2HGDH gene: neuroimaging findings. , 2008, Neuropediatrics.

[39]  O. Snead,et al.  Metabolism of gamma-hydroxybutyrate to d-2-hydroxyglutarate in mammals: further evidence for d-2-hydroxyglutarate transhydrogenase. , 2006, Metabolism: clinical and experimental.

[40]  E. Struys.  D-2-Hydroxyglutaric aciduria: Unravelling the biochemical pathway and the genetic defect , 2006, Journal of Inherited Metabolic Disease.

[41]  K. Gibson,et al.  Kinetic characterization of human hydroxyacid–oxoacid transhydrogenase: Relevance toD-2-hydroxyglutaric and γ-hydroxybutyric acidurias , 2005, Journal of Inherited Metabolic Disease.

[42]  S. Korman,et al.  Mutations in phenotypically mild D‐2‐hydroxyglutaric aciduria , 2005, Annals of Neurology.

[43]  W. Craigen,et al.  Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria. , 2005, American journal of human genetics.

[44]  R. Rzem,et al.  A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Lathrop,et al.  L-2-Hydroxyglutaric aciduria: identification of a mutant gene C14orf160, localized on chromosome 14q22.1. , 2004, Human molecular genetics.

[46]  N. Verhoeven,et al.  Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride. , 2004, Clinical chemistry.

[47]  G. Finocchiaro,et al.  L-2-hydroxyglutaric aciduria and brain malignant tumors , 2004, Neurology.

[48]  N. Verhoeven,et al.  Disease-related metabolites in culture medium of fibroblasts from patients with D-2-hydroxyglutaric aciduria, L-2-hydroxyglutaric aciduria, and combined D/L-2-hydroxyglutaric aciduria. , 2003, Clinical chemistry.

[49]  M. Topcu,et al.  Medulloblastoma in a Child with the Metabolic Disease L-2-Hydroxyglutaric Aciduria , 2002, Pediatric Neurosurgery.

[50]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[51]  Jeffrey W. Clark,et al.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.